Results from Xeltis’ first feasibility clinical trial have been presented at the annual Heart Valve Society Scientific Meeting in New York City on 17 March by leading investigator and world-renowned cardiac surgeon, Professor Leo Bockeria. The results of the study conducted in five pediatric patients implanted a bioabsorbable vascular graft showed significant improvement in patients’ general condition, positive device anatomical and functional stability and no device-related adverse events in all patients a year after surgery.
